Exosomal LncRNA HOTTIP Mediates Antiviral Effect of Tenofovir Alafenamide (TAF) on HBV Infection

Overview

Journal J Inflamm Res

Publisher Dove Medical Press

Date 2021 Nov 1

PMID 34720597

Citations 4

Authors

Qing-Min Liu

Yi-Yu He

Li-Li Liu

Li-Kun Wang

Affiliations

Soon will be listed here.

Abstract

Introduction: Chronic hepatitis B (CHB) virus (HBV) infection has emerged as a global health burden affecting nearly 292 million people. Tenofovir alafenamide (TAF) is an effective treatment for CHB patients. However, the detailed mechanism underlying the antiviral activity of TAF remains unclear.

Methods: In this study, we investigated the antiviral effect of exosomes derived from the serum of CHB patients treated with TAF (Exo-serum) and TAF-treated macrophages (MP) (Exo-MP(TAF)).

Results: RNAseq analysis was also performed to determine the associated long non-coding RNAs (lncRNAs). The results demonstrated that both Exo-serum and Exo-MP(TAF) could be taken up by HepAD38 cells and exhibited potent antiviral activities, as manifested by significantly downregulating the levels of hepatitis B surface antigen, hepatitis B e antigen, HBV DNA, and covalently closed circular DNA. The antiviral effect of Exo-serum was more potent than those of TAF treatment alone. RNAseq analysis revealed that lncRNA HOTTIP was upregulated significantly in Exo-serum. Further, lncRNA HOTTIP knockdown reversed the antiviral effect of Exo-MP(TAF) on HepAD38 cells, whereas lncRNA HOTTIP knockdown exerted the opposite roles.

Discussion: Taken together, these results suggest that exosomal lncRNA HOTTIP is essential for the antiviral activity of TAF and provide a novel understanding of the exosome-mediated mechanism underlying HBV infection.

Citing Articles

Extracellular Vesicles in Viral Liver Diseases.

Kouroumalis E, Tsomidis I, Voumvouraki A Viruses. 2024; 16(11).

PMID: 39599900 PMC: 11598962. DOI: 10.3390/v16111785.

Exosomes target HBV-host interactions to remodel the hepatic immune microenvironment.

Wu X, Niu J, Shi Y J Nanobiotechnology. 2024; 22(1):315.

PMID: 38840207 PMC: 11151510. DOI: 10.1186/s12951-024-02544-y.

Roles of small extracellular vesicles in the development, diagnosis and possible treatment strategies for hepatocellular carcinoma (Review).

Yang S, Wang J, Wang S, Zhou A, Zhao G, Li P Int J Oncol. 2022; 61(2).

PMID: 35674180 PMC: 9262158. DOI: 10.3892/ijo.2022.5381.

Diversity of Dysregulated Long Non-Coding RNAs in HBV-Related Hepatocellular Carcinoma.

Samudh N, Shrilall C, Arbuthnot P, Bloom K, Ely A Front Immunol. 2022; 13:834650.

PMID: 35154157 PMC: 8831247. DOI: 10.3389/fimmu.2022.834650.

References

Serghiou S, Kyriakopoulou A, Ioannidis J . Long noncoding RNAs as novel predictors of survival in human cancer: a systematic review and meta-analysis. Mol Cancer. 2016; 15(1):50. PMC: 4924330. DOI: 10.1186/s12943-016-0535-1. View

Han M, Li Y, Wu W, Zhang Y, Yan W, Luo X . Altered expression of interferon-stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection. Antiviral Res. 2017; 147:75-85. DOI: 10.1016/j.antiviral.2017.10.003. View

Pefanis E, Wang J, Rothschild G, Lim J, Kazadi D, Sun J . RNA exosome-regulated long non-coding RNA transcription controls super-enhancer activity. Cell. 2015; 161(4):774-89. PMC: 4428671. DOI: 10.1016/j.cell.2015.04.034. View

Wu D, Wang P, Han M, Chen Y, Chen X, Xia Q . Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study. Hepatol Int. 2019; 13(5):573-586. DOI: 10.1007/s12072-019-09956-1. View

Li X, Zhao J, Yuan Q, Xia N . Detection of HBV Covalently Closed Circular DNA. Viruses. 2017; 9(6). PMC: 5490816. DOI: 10.3390/v9060139. View

Lu J, Xie F, Geng L, Shen W, Sui C, Yang J . Investigation of serum lncRNA-uc003wbd and lncRNA-AF085935 expression profile in patients with hepatocellular carcinoma and HBV. Tumour Biol. 2014; 36(5):3231-6. DOI: 10.1007/s13277-014-2951-4. View

Lin C, Yang H, Kao J . Hepatitis B virus: new therapeutic perspectives. Liver Int. 2016; 36 Suppl 1:85-92. DOI: 10.1111/liv.13003. View

Yilmaz Susluer S, Kayabasi C, Ozmen Yelken B, Asik A, Celik D, Balci Okcanoglu T . Analysis of long non-coding RNA (lncRNA) expression in hepatitis B patients. Bosn J Basic Med Sci. 2018; 18(2):150-161. PMC: 5988534. DOI: 10.17305/bjbms.2018.2800. View

Li J, Liu K, Liu Y, Xu Y, Zhang F, Yang H . Exosomes mediate the cell-to-cell transmission of IFN-α-induced antiviral activity. Nat Immunol. 2013; 14(8):793-803. DOI: 10.1038/ni.2647. View

10.

Buti M, Gane E, Seto W, Chan H, Chuang W, Stepanova T . Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2017; 1(3):196-206. DOI: 10.1016/S2468-1253(16)30107-8. View

11.

Ren F, Ren J, Song C, Tan M, Yu H, Zhou Y . LncRNA HOTAIR modulates hepatitis B virus transcription and replication by enhancing SP1 transcription factor. Clin Sci (Lond). 2020; 134(22):3007-3022. DOI: 10.1042/CS20200970. View

12.

Hermansson L, Yilmaz A, Price R, Nilsson S, McCallister S, Makadzange T . Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate. PLoS One. 2019; 14(12):e0226276. PMC: 6905536. DOI: 10.1371/journal.pone.0226276. View

13.

Uchida Y, Nakao M, Tsuji S, Uemura H, Kouyama J, Naiki K . Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate. J Med Virol. 2019; 92(3):329-338. DOI: 10.1002/jmv.25644. View

14.

Wu J, Niu Q, Yuan J, Xu X, Cao L . lncRNA-CD160 decreases the immunity of CD8 T cells through epigenetic mechanisms in hepatitis B virus infection. Oncol Lett. 2020; 20(1):235-247. PMC: 7286002. DOI: 10.3892/ol.2020.11534. View

15.

Kouwaki T, Fukushima Y, Daito T, Sanada T, Yamamoto N, Mifsud E . Extracellular Vesicles Including Exosomes Regulate Innate Immune Responses to Hepatitis B Virus Infection. Front Immunol. 2016; 7:335. PMC: 5005343. DOI: 10.3389/fimmu.2016.00335. View

16.

Garcia-Contreras M, Shah S, Tamayo A, Robbins P, Golberg R, Mendez A . Plasma-derived exosome characterization reveals a distinct microRNA signature in long duration Type 1 diabetes. Sci Rep. 2017; 7(1):5998. PMC: 5519761. DOI: 10.1038/s41598-017-05787-y. View

17.

Yao Z, Qiao Y, Li X, Chen J, Ding J, Bai L . Exosomes Exploit the Virus Entry Machinery and Pathway To Transmit Alpha Interferon-Induced Antiviral Activity. J Virol. 2018; 92(24). PMC: 6258946. DOI: 10.1128/JVI.01578-18. View

18.

Li R, Fu X, Tang Y, Fu L, Tan D, Ouyang Y . [Expression profiles of the exosomal miRNAs in the chronic hepatitis B patients with persistently normal ALT]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2018; 43(5):475-480. DOI: 10.11817/j.issn.1672-7347.2018.05.003. View

19.

Goodyear M, Krleza-Jeric K, Lemmens T . The Declaration of Helsinki. BMJ. 2007; 335(7621):624-5. PMC: 1995496. DOI: 10.1136/bmj.39339.610000.BE. View

20.

Dore G, Cowie B . Global Hepatitis B Virus Elimination by 2030: China Is Pivotal and Instructive. Clin Infect Dis. 2020; 72(5):753-754. DOI: 10.1093/cid/ciaa138. View